[Novel therapeutic approach to amyloidosis: no implications as yet for patients with Alzheimer's disease].
Many disorders, such as Alzheimer's disease and diabetes, are characterised by the misfolding and aggregation of proteins. Pepys et al. described a new approach of destabilizing these aggregates by removing an associated protein, serum amyloid P. This offers opportunities for treating amyloidosis and possibly other protein folding diseases. Understanding the mechanism of this unique disease process and the different elements involved is necessary for future drug development.
D000544:Alzheimer Disease / Q000188:drug therapy*; D000686:Amyloidosis / Q000188:drug therapy*; D002264:Carboxylic Acids / Q000627:therapeutic use*; D006801:Humans; D017510:Protein Folding; D011759:Pyrrolidines / Q000627:therapeutic use*; D000683:Serum Amyloid P-Component / Q000187:drug effects* / Q000378:metabolism
D002264:Carboxylic Acids; D011759:Pyrrolidines; C455899:R-1-(6-(R-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid; D000683:Serum Amyloid P-Component
Nieuwe therapeutische benadering van amyloïdose: vooralsnog geen implicaties voor patiënten met de ziekte van Alzheimer.